FDA allows standalone use of nasal spray antidepressant Spravato (esketamine)

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its own. It was approved in 2019 to treat severe depression.

Jan 21, 2025 - 23:37
 0
FDA allows standalone use of nasal spray antidepressant Spravato (esketamine)
Spravato, the brand name for esketamine, has a newly approved indication for treatment-resistant depression.

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its own. It was approved in 2019 to treat severe depression.

(Image credit: tadamichi/Getty Images/iStockphoto)

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow